title: Selective Efficacy of Temsirolimus on Bone Metastases in Chromophobe Renal Cell Carcinoma.
authors.affiliation: Department of Radiation Oncology, The University of Texas Southwestern Medical Center, Dallas, TX; Kidney Cancer Program, Simmons Comprehensive Cancer Center, The University of Texas Southwestern Medical Center, Dallas, TX.
authors.forename: Lorel
authors.initials: L
authors.lastname: Huelsmann
authors.affiliation: Department of Radiation Oncology, The University of Texas Southwestern Medical Center, Dallas, TX; Kidney Cancer Program, Simmons Comprehensive Cancer Center, The University of Texas Southwestern Medical Center, Dallas, TX.
authors.forename: D Nathan W
authors.initials: DNW
authors.lastname: Kim
authors.affiliation: Department of Radiation Oncology, The University of Texas Southwestern Medical Center, Dallas, TX.
authors.forename: Raquibul
authors.initials: R
authors.lastname: Hannan
authors.affiliation: Department of Radiology, The University of Texas Southwestern Medical Center, Dallas, TX.
authors.forename: Lori M
authors.initials: LM
authors.lastname: Watumull
authors.affiliation: Kidney Cancer Program, Simmons Comprehensive Cancer Center, The University of Texas Southwestern Medical Center, Dallas, TX; Internal Medicine, Medical Oncology Division/Developmental Biology, The University of Texas Southwestern Medical Center, Dallas, TX. Electronic address: James.Brugarolas@UTSouthwestern.edu.
authors.forename: James
authors.initials: J
authors.lastname: Brugarolas
mesh_terms: D000368:Aged; D001859:Bone Neoplasms / Q000188:drug therapy* / Q000556:secondary; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000473:pathology; D018450:Disease Progression; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D000076222:Mechanistic Target of Rapamycin Complex 1; D046912:Multiprotein Complexes / Q000037:antagonists & inhibitors; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage* / Q000627:therapeutic use; D020123:Sirolimus / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D058570:TOR Serine-Threonine Kinases / Q000037:antagonists & inhibitors; D016896:Treatment Outcome
chemical_list: D046912:Multiprotein Complexes; D047428:Protein Kinase Inhibitors; C401859:temsirolimus; D000076222:Mechanistic Target of Rapamycin Complex 1; D058570:TOR Serine-Threonine Kinases; D020123:Sirolimus
keywords: Bone remodeling; Everolimus; Mammalian target of rapamycin (mTOR); Osteoclasts; Tuberous Sclerosis Complex 1 (TSC1)